Some scientists thought that fat around the organs might make too much of the stress hormone cortisol locally, which could make people gain weight—but after looking at many studies, it seems this probably isn’t a big reason for obesity.
Scientific Claim
Visceral adipose tissue (VAT) intracellular hypercortisolism, mediated by 11β-hydroxysteroid dehydrogenase type I (11-HSD-1) activity, may be associated with human obesity, but current evidence suggests it is possible but unlikely to be a major driver.
Original Statement
“The current review summarizes the evidence published so far about this possibility... Our conclusion is that the presence of VAT intracellular hypercortisolism in human obesity is possible but unlikely.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract uses cautious language ('possible but unlikely') consistent with a narrative review lacking original data. No causal or definitive claims are made, and the verb strength appropriately reflects the evidence level.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether VAT 11-HSD-1 activity is consistently elevated in obese vs. non-obese humans across diverse populations, and whether this elevation correlates with metabolic dysfunction.
Whether VAT 11-HSD-1 activity is consistently elevated in obese vs. non-obese humans across diverse populations, and whether this elevation correlates with metabolic dysfunction.
What This Would Prove
Whether VAT 11-HSD-1 activity is consistently elevated in obese vs. non-obese humans across diverse populations, and whether this elevation correlates with metabolic dysfunction.
Ideal Study Design
A systematic review and meta-analysis of 20+ high-quality studies measuring VAT 11-HSD-1 enzyme activity via biopsy in 500+ adults (BMI ≥30 vs. BMI 18.5–24.9), matched for age, sex, and metabolic health, with standardized assays and adjustment for confounders like insulin resistance and glucocorticoid use.
Limitation: Cannot prove causation or determine if elevated 11-HSD-1 is a cause or consequence of obesity.
Randomized Controlled TrialLevel 1bWhether pharmacologically inhibiting 11-HSD-1 in VAT improves metabolic outcomes in obese individuals, supporting a causal role for local cortisol excess.
Whether pharmacologically inhibiting 11-HSD-1 in VAT improves metabolic outcomes in obese individuals, supporting a causal role for local cortisol excess.
What This Would Prove
Whether pharmacologically inhibiting 11-HSD-1 in VAT improves metabolic outcomes in obese individuals, supporting a causal role for local cortisol excess.
Ideal Study Design
A double-blind, placebo-controlled RCT of 150 obese adults with metabolic syndrome, randomized to 12 weeks of a selective 11-HSD-1 inhibitor (e.g., AZD4017, 10mg/day) vs. placebo, measuring primary outcomes: VAT cortisol levels (microdialysis), fasting glucose, HOMA-IR, and liver fat (MRI).
Limitation: Does not prove that endogenous VAT hypercortisolism exists—only that blocking it has effects.
Prospective Cohort StudyLevel 2bWhether baseline VAT 11-HSD-1 activity predicts future weight gain or metabolic disease development in initially healthy individuals.
Whether baseline VAT 11-HSD-1 activity predicts future weight gain or metabolic disease development in initially healthy individuals.
What This Would Prove
Whether baseline VAT 11-HSD-1 activity predicts future weight gain or metabolic disease development in initially healthy individuals.
Ideal Study Design
A 5-year prospective cohort of 1000 healthy adults (age 30–50) with baseline VAT 11-HSD-1 activity measured via biopsy or PET imaging, tracking incident obesity (BMI ≥30), type 2 diabetes, and dyslipidemia, adjusting for diet, activity, and genetics.
Limitation: Cannot rule out reverse causation or unmeasured confounders.
Case-Control StudyLevel 3Whether individuals with severe central obesity have significantly higher VAT 11-HSD-1 activity than BMI-matched controls without metabolic dysfunction.
Whether individuals with severe central obesity have significantly higher VAT 11-HSD-1 activity than BMI-matched controls without metabolic dysfunction.
What This Would Prove
Whether individuals with severe central obesity have significantly higher VAT 11-HSD-1 activity than BMI-matched controls without metabolic dysfunction.
Ideal Study Design
A matched case-control study comparing VAT 11-HSD-1 activity in 50 obese individuals with metabolic syndrome vs. 50 BMI-matched obese without metabolic syndrome, using standardized biopsy and mass spectrometry for cortisol/cortisone ratios.
Limitation: Cross-sectional design cannot determine temporal sequence or causality.
Cross-Sectional StudyLevel 4Whether VAT 11-HSD-1 activity correlates with circulating or local cortisol levels in obese adults at a single time point.
Whether VAT 11-HSD-1 activity correlates with circulating or local cortisol levels in obese adults at a single time point.
What This Would Prove
Whether VAT 11-HSD-1 activity correlates with circulating or local cortisol levels in obese adults at a single time point.
Ideal Study Design
A cross-sectional study of 200 obese adults measuring VAT 11-HSD-1 mRNA, protein, and enzyme activity via biopsy, alongside paired portal and peripheral cortisol/cortisone ratios, controlling for time of day and stress levels.
Limitation: Only shows association at one point in time; cannot infer directionality or causation.
Evidence from Studies
Supporting (1)
Is There Visceral Adipose Tissue (VAT) Intracellular Hypercortisolism in Human Obesity?
Scientists looked at whether fat around the organs makes too much of the stress hormone cortisol locally, and if that causes obesity. They found it might happen, but probably isn’t a big reason people get obese.